ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
64,326.33
0.51%
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
0.00%
US Dollar vs Yen
153.772
0.13%
Brent Oil
83.475
0.42%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Acadia Pharmaceuticals Inc (ACAD)

  7. Acadia Pharmaceuticals Inc (ACAD) ニュース

ACAD

Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ACAD
日付受信時刻ニュースソース見出しコード企業名
2024/04/3005 : 16Business WireAcadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/04/2505 : 05Business WireAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
2024/04/2222 : 04Business WireAcadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé CanadaNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/04/2222 : 04Business WireAcadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health CanadaNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/04/2005 : 05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
2024/04/1805 : 05Business WireAcadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual MeetingNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/04/0305 : 05Business WireAcadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and DevelopmentNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/04/0205 : 05Business WireAcadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/03/1605 : 05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
2024/03/1405 : 05Business WireAcadia Pharmaceuticals to Participate in the UBS Virtual CNS DayNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/03/1220 : 21IH Market NewsOracle Soars 13% With Exceptional Growth and Boosts Nvidia Shares With Collaboration Announcement, and MoreNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/03/1205 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/03/1205 : 05Business WireAcadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of SchizophreniaNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/2923 : 05Business WireAcadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/2808 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/2808 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/2808 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/2808 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/2806 : 16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/2806 : 05Business WireAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/2206 : 05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/1421 : 08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/1406 : 05Business WireAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/0907 : 09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/02/0907 : 05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/01/3111 : 55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/01/3110 : 48Business WireAcadia Announces Additions to Executive TeamNASDAQ:ACADAcadia Pharmaceuticals Inc
2024/01/2707 : 25Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACADAcadia Pharmaceuticals Inc
2024/01/2006 : 05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
2024/01/1906 : 05Business WireAcadia Announces the Passing of Former President Srdjan (Serge) StankovicNASDAQ:ACADAcadia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACAD

最近閲覧した銘柄

NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
CCOM
US30
US 30
NASDAQ
GOOGL
Alphabet
NYSE
CVX
Chevron
NYSE
JPM
JP Morgan Chase
FX
USDJPY
US Dollar vs Yen
CCOM
SILVER
SILVER
USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
FX
USDGBP
US Dollar vs Sterling
NYSE
XOM
Exxon Mobil
NASDAQ
AMZN
Amazon.com
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有